

(19)



Europäische Patentamt  
Europatentamt  
Office européen des brevets



(11)

EP 0 950 402 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
14.05.2003 Bulletin 2003/20

(51) Int Cl.7: A61K 9/00, A61K 9/20

(21) Application number: 99301263.2

(22) Date of filing: 22.02.1999

(54) Chewable pharmaceutical composition with gelatin matrix

Kaubare pharmazeutischer Zusammensetzung mit Gelatinematrix

Composition pharmaceutique à mâcher à matrice de gélatine

(84) Designated Contracting States:  
BE DE ES FR GB IT

• Bunick, Frank J.  
Randolph, NJ (US)

(30) Priority: 23.02.1998 US 27629

(74) Representative: Mercer, Christopher Paul et al

(43) Date of publication of application:  
20.10.1999 Bulletin 1999/42

Carpmaels & Ransford  
43, Bloomsbury Square  
London WC1A 2RA (GB)

(73) Proprietor: McNEIL-PPC, Inc.  
Skillman, New Jersey 08558 (US)

(56) References cited:

EP-A- 0 190 826      EP-A- 0 227 603  
EP-A- 0 282 453      EP-A- 0 502 666  
EP-A- 0 553 777      EP-A- 0 890 358  
WO-A-95/20377      US-A- 4 857 331

(72) Inventors:  
• Buehler, Gail K.  
Lower Gwynedd, PA 19002 (US)

EP 0 950 402 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Printed by Jouve, 75001 PARIS (FR)

BEST AVAILABLE COPY